Current Views on Predictors and Biomarkers of Early Diagnosis of Anthracycline-Mediated Cardiotoxicity in Patients With Breast Cancer (Review of Literature)

Gvaldin, Dmitry Yu.; Omelchuk, Ekaterina P.

doi:10.18821/0869-2084-2020-65-3-141-148

RCLD

2020

DOI: 10.18821/0869-2084-2020-65-3-141-148

|View full text |Cite

Current Views on Predictors and Biomarkers of Early Diagnosis of Anthracycline-Mediated Cardiotoxicity in Patients With Breast Cancer (Review of Literature)

Dmitry Yu. Gvaldin

Ekaterina P. Omelchuk

Abstract: Anthracyclines are effectively used in many therapeutic regimens for breast cancer (BC). However, the dose-dependent cardiotoxic effect causes certain limitations on their use. Laboratory tests for risk prediction and early diagnosis of anthracycline-induced cardiotoxicity (ACIC) based on measuring the activity and concentration of topoisomerase 2β, the levels of troponins T and I (TnT и TnI), N-terminal fragment of brain natriuretic peptide progenitor, remain relevant, but complicate the risk stratification w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The Role of Molecular Genetic Studies in Current Oncology

Maksimov¹,

Dzhenkova²,

Тимошкина³

2022

Annals RAMS

View full text Add to dashboard Cite

Genetic information, both inherited and tumor-specific, is becoming an increasingly important factor in the implementation of therapeutic strategies in oncology, providing an individual approach to each patient. Every year, an increasing number of achievements in medical genetics are introduced into oncological practice in the form of laboratory tests, diagnostic panels and practical recommendations. The article provides a brief overview of the results of genetic studies performed at the Federal National Medical Research Centre for Oncology of the Ministry of Health of the Russian Federation from the beginning of their implementation in 2013 to the present day. We have demonstrated not only testing data within the framework of clinical recommendations, but also an analysis of the search for new genetic, epigenetic and proteomic markers, which seem promising for the development of new target drugs, diagnostic and prognostic test systems. We believe that the model of interaction between a researcher and an oncologist used in our center allows us to shorten the path from a scientific hypothesis to the creation and implementation of innovative technologies.

show abstract

The Role of Molecular Genetic Studies in Current Oncology

Maksimov¹,

Dzhenkova²,

Тимошкина³

2022

Annals RAMS

View full text Add to dashboard Cite

show abstract

RS4673 and pon1 level in blood plasma – new prospects in prediction and early diagnostics of anthracycline-mediated cardiotoxicity

Gvaldin¹,

Тимошкина²,

Vashchenko³

et al. 2022

Klin. lab. diagn.

View full text Add to dashboard Cite

The purpose of this study was to research the effectiveness of molecular genetic tests based on the determination of the rs4673 CYBA polymorphism (c.242C>T) and the level of paraoxonase 1 (PON1) in the blood plasma of patients with breast cancer (BC) for predicting and diagnosing anthracycline-mediated cardiotoxicity (AMC). The genotyping of rs4673 CYBA (c.242C>T) and the study of the PON1 level in the blood plasma of 280 patients of the Caucasian type with a histologically verified diagnosis of breast cancer, who received complex treatment on the basis of the National Medical Research Center of Oncology, were carried out. Based on the results of observation for at least 8 months, two groups were identified: group 1 (257 people) without diagnosed cardiovascular changes; group 2 (23 people) - patients with subacute and early chronic AMC. It was found that carriers of the rs4673 polymorphism increase the likelihood of developing AMC by 6.8 times (p = 0.001). In the blood plasma of both groups of patients, an increase in the level of PON1 was described after the fourth course compared to the initial level (group 1 - p = 0.036, group 2 - p = 0.048). The level of the studied enzyme was higher in the blood plasma of patients with diagnosed AMC compared with patients without cardiovascular complications (before chemotherapy - p = 0.001, after the fourth course - p = 0.023). The test based on the measurement of the concentration of PON1 in the blood plasma of patients after the fourth course of chemotherapy was distinguished by high quality metrics: sensitivity - 100%, specificity - 70.8%, area under the ROC-curve (AUC) - 0.825 with a threshold level of PON1 equal to 2, 9 ng/μL. The presence of the T/T genotype caused a high level of PON1 in the blood plasma after the fourth course of chemotherapy (p = 0.012). The results of our work are of undoubted practical importance, since they allow us to obtain data on the prognosis and diagnosis of a patient in a short time, which can later be verified using clinical and instrumental methods.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Current Views on Predictors and Biomarkers of Early Diagnosis of Anthracycline-Mediated Cardiotoxicity in Patients With Breast Cancer (Review of Literature)

Cited by 2 publications

References 20 publications

The Role of Molecular Genetic Studies in Current Oncology

The Role of Molecular Genetic Studies in Current Oncology

RS4673 and pon1 level in blood plasma – new prospects in prediction and early diagnostics of anthracycline-mediated cardiotoxicity

Contact Info

Product

Resources

About